New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 8124-8134

  Yea, Christopher M ^a   Allan, Christine E ^a   Ashworth, Doreen M ^b   Barnett, James ^b   Baxter, Andy J ^b   Broadbridge, Janice D ^b   Franklin, Richard J ^b   Hampton, Sally L ^a   Hudson, Peter ^b   Horton, John A ^b   Jenkins, Paul D ^b   Penson, Andy M ^b   Pitt, Gary R W ^b   Rivière, Pierre ^c   Robson, Peter A ^a   Rooker, David P ^a   Semple, Graeme ^b   Sheppard, Andy ^a   Haigh, Robert M ^a   Roe, Michael B ^a  

^a Vantia Ltd   (United Kingdom)

^b Ferring Research Ltd   (United Kingdom)

^c Ferring Pharmaceuticals AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 METHYL 4 (2,3,4,5 TETRAHYDRO 1 BENZAZEPIN 1 YLCARBONYL)BENZYLCARBAMOYL]PROLINE N,N DIMETHYLAMIDE; BENZYLUREA DERIVATIVE; DESMOPRESSIN; OPC 51803; UNCLASSIFIED DRUG; VA 106483; VASOPRESSIN; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR AGONIST; VNA 932;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIURESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RAT; RECEPTOR UPREGULATION; SUBSTITUTION REACTION; URINE VOLUME; VASOPRESSIN RELEASE; WATER PERMEABILITY;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; DIURESIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, CHEMICAL; RATS; RATS, BRATTLEBORO; RECEPTORS, VASOPRESSIN; SOLUBILITY; UREA;

EID: 58149093623     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8008162     Document Type: Article

References (29)

1. Altura, B. M.; Altura, B. T. Vascular smooth muscle and neurohypophyseal hormones. Fed. Proc. 1977, 36, 1853-1860.
2. Howl, J.; Ismail, T.; Strain, A. J.; Kirk, C. J.; Anderson, D.; Wheatley, M. Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function. Biochem. J. 1991, 276 (1), 189-195.
3. Jard, S.; Lombard, C.; Marie, J.; Devilliers, G. Vasopressin receptors from cultured mesangial cells resemble V1a type. Am. J. Physiol. 1987, 253 (1 Pt 2), F41-F49.
4. Penit, J.; Faure, M.; Jard, S. Vasopressin and angiotensin II receptors in rat aorta smooth muscle cells in culture. Am. J. Physiol. 1983, 244 (1), E72-E82.
5. Thibonnier, M.; Roberts, J. M. Characterization of human platelet vasopressin receptors. J. Clin. Invest. 1985, 76, 1857-1864.
6. Laski, M. E.; Pressley, T. A. Aquaporin mediated water flux as a target for diuretic development. Semin. Nephrol. 1999, 19 (6), 533-550.
7. Dorsa, D. M.; Majumdar, L. A.; Petracca, F. M.; Baskin, D. G.; Cornett, L. E. Characterization and localization of 3H-arginine8-vasopressin binding to rat kidney and brain tissue. Peptides 1983, 4, 699-706.
8. Andersson, K. E.; Bengtsson, B.; Paulsen, O. Desamino-8-D- arginine vasopressin (DDAVP): pharmacology and clinical use. Drugs Today (Barc) 1988, 24 (7), 509-528.
9. Skoog, S. J.; Stokes, A.; Turner, K. L. Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis. J. Urol. 1997, 158 (3 Pt 2), 1035-1040.
10. (a) Kondo, K.; Ogawa, H.; Shinohara, T.; Kurimura, M.; Tanada, Y.; Kan, K.; Yamashita, H.; Nakamura, S.; Hirano, T.; Yamamura, Y.; Mori, T.; Tominaga, M.; Itai, A. Novel Design of Nonpeptide AVP V2 Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H- 1-benzazepine as a Template. J. Med. Chem. 2000, 43, 4388-4397.
11. (b) Kondo, K.; Kan, K.; Tananda, Y.; Bando, M.; Shinohara, T.; Kurimura, M.; Ogawa, H.; Nakamura, S.; Hirano, T.; Yamamura, Y.; Kido, M.; Mori, T.; Tominaga, M. Characterization of orally active nonpeptide vasopressin V2 receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-chloro-4-pyrrolidin-1-ylbenzoyl)-2,3, 4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide. J. Med. Chem. 2002, 45, 3805-3808.
12. Caggiano, T. J. WAY-VNA-932. Drugs Future 2002, 27, 248-253.
13. Pitt, G. R. Non-Peptide Vasopressin V2 Receptor Agonists. Abstracts of Papers, RSC-SCI Symposium on Medicinal Chemistry, September 9-12, 2001.
14. Pitt, G. R. W.; Batt, A. R.; Haigh, R. M.; Penson, A. M.; Robson, P. A.; Rooker, D. P.; Tartar, A. L.; Trim, J. E.; Yea, C. M.; Roe, M. B. Non-peptide oxytocin agonists. Bioorg. Med. Chem. Lett. 2004, 14, 4585-4589.
15. Ashworth, D. M.; Pitt, G. R. W.; Hudson, P.; Yea, C. M.; Franklin, R. J.; Semple, G. Preparation of fused azepine derivatives and their use as antidiuretic agents. PCT Int. Appl. WO 000626 A1, 2002.
16. Hudson, P.; Batt, A. R.; Laurent, C. M. S.; Baxter, A. J.; Roe, M. B.; Robson, P. A. Preparation of substituted pyrazolo-fused benzodiazepine analogs as oxytocin agonists and vasopressin antagonists. Eur. Pat. Appl. EP 1449844 A1, 2004.
17. Chiba, J.; Takayama, G.; Takashi, T.; Yokoyama, M.; Nakayama, A.; Baldwin, J. J.; McDonald, E.; Moriarty, K. J.; Sarko, C. R.; Saionz, K. W.; Swanson, R.; Hussain, Z.; Wong, A.; Machinaga, N. Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. Bioorg. Med. Chem. 2006, 14, 2725-2746.
18. Smith, E. M.; Swiss, G. F.; Neustadt, B. R.; Gold, E. H.; Sommer, J. A.; Brown, A. D.; Chiu, P. J. S.; Moran, R.; Sybertz, E. J.; Baum, T. Synthesis and pharmacological activity of angiotensin-converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines. J. Med. Chem. 1988, 31, 875-885.
19. Cho, H.; Murakami, K.; Nakanishi, H.; Isoshima, H.; Hayakawa, K.; Uchida, I. Regioselective synthesis of several heterocyclic fused azepines using diisobutylaluminum hydride. Heterocycles 1998, 48, 919-927.
20. Albright, J. D.; Reich, M. F.; Delos Santos, E. G.; Dusza, J. P.; Sum, F.-W.; Venkatesan, A. M.; Coupet, J.; Chan, P. S.; Ru, X.; Mazandarani, H.; Bailey, T. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4] benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem. 1998, 41, 2442-2444.
21. Ohta, T.; Miyake, S.; Shudo, K. A trifluoromethanesulfonic acid-catalyzed reaction of arylhydrazines with benzene. Tetrahedron Lett. 1985, 26, 5811-5814.
22. Chimenti, F.; Vomero, S.; Giuliano, R.; Artico, M. Research on substances having antiblastic activity. Note LIX. Anthramycin and related compounds. Part VIII: Synthesis of 4H-pyrrolo[1,2-a][1,5]benzodiazepine derivatives. Farmaco, Ed. Sci. 1977, 32, 339-347.
23. (a) Schmale, H.; Richter, D. Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature 1984, 308, 705-709.
24. (b) Valtin, H.; Schroeder, H. A. Familial hypothalamic diabetes insipidus in rats (Brattleboro strain). 1964. J. Am. Soc. Nephrol. 1997, 8, 1333-1341.
25. Trybulski, E. J. Vasopressin Receptor Modulators: From Non-peptide Antagonists to Agonists. In Annual Reports in Medicinal Chemistry, Volume 36; Doherty, A. M., Ed.; Academic Press: San Diego, 2001; pp 159-168.
26. Sum, F.-W.; Dusza, J.; Santos, E. D.; Grosu, G.; Reich, M.; Du, X.; Albright, J. D.; Chan, P.; Coupet, J.; Ru, X.; Mazandarani, H.; Saunders, T. Structure-Activity Study of Novel Tricyclic Benzazepine Arginine Vasopressin Antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 2195-2198.
27. Kondo, K.; Ogawa, H.; Yamashita, H.; Miyamoto, H.; Tanaka, M.; Nakaya, K.; Kitano, K.; Yamamura, Y.; Nakamura, S.; Onogawa, T.; Mori, T.; Tominaga, M. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5 -tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg. Med. Chem. 1999, 7, 1743-1757.
28. Chio, C. L.; Lajiness, M. E.; Huff, R. M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 1994, 45, 51-60.
29. Kenakin, T. A Pharmacology Primer: Theory, Application and Methods; Elsevier Academic Press: San Diego, 2004; pp 73-92.